Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya

AIDS and Behavior

Volumn 19, Issue 5, 2015, Pages 794-801

  Mugo, Peter Mwangi ^a   Sanders, Eduard J ^a,b   Mutua, Gaudensia ^c   van der Elst, Elisabeth ^a   Anzala, Omu ^c   Barin, Burc ^d   Bangsberg, David R ^e,f   Priddy, Frances H ^g   Haberer, Jessica E ^e,f  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d EMMES CORPORATION   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

HIV; Intermittent PrEP adherence; Men who have sex with men; Pre exposure prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE; TENOFOVIR;

CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HIV INFECTIONS; HUMAN; KENYA; MALE; MALE HOMOSEXUALITY; MEDICATION COMPLIANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EMTRICITABINE; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; KENYA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PRE-EXPOSURE PROPHYLAXIS; SOCIOECONOMIC FACTORS; TENOFOVIR;

EID: 84939977586     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0958-x     Document Type: Article

References (32)

1. UNAIDS. Report on the global AIDS epidemic: Joint United Nations Programme on HIV/AIDS (UNAIDS). 2013.
2. Beyrer C, Baral SD, Walker D, Wirtz AL, Johns B, Sifakis F. The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. Epidemiol Rev. 2010;32(1):137–51.
3. Price MA, Rida W, Mwangome M, et al. Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr. 2012;59(2):185–93.
4. Sanders EJ, Okuku HS, Smith AD, et al. High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads following seroconversion among MSM. AIDS. 2013;27(3):437–46.
5. Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet. 2009;374(9687):416–22.
6. KNACC. Kenya National AIDS Strategic Plan 2009–2013: Kenya National AIDS Control Council. 2009.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
8. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
9. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.
10. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
11. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.
12. MTN. Daily HIV prevention approaches didn’t work for African women in the VOICE study. Pittsburgh: Microbicide Trials Network; 2013.
13. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–9.
14. WHO. Guidance on Pre-exposure oral prophylaxis (prep) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV. Geneva: World Health Organization; 2012.
15. SAHCS. Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. The Consensus Committee, Southern African HIV Clinicians Society; 2012.
16. AVAC. PrEP research to rollout: a schematic road map. AVAC; 2011.
17. AVAC. Ongoing and planned PrEP trials and demonstration projects as of August 2013. AVAC; 2013.
18. Buchbinder SP, Glidden DV, Liu AY, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect. Dis. 2014; 14(6):468–475.
19. Liu A, Cohen S, Follansbee S, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(3):e1001613.
20. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.
21. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10(3):e1001401.
22. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):e28.
23. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2010;2(14):14ra14.
24. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 2012;4(151):151ra125.
25. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE. 2012;7(4):e33103.
26. Van der Elst EM, Mbogua J, Operario D, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012;17(6):2162–2172.
27. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42(1):49–54.
28. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.
29. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17(6):2143–55.
30. Psaros C. Evaluation and Process Outcomes from an adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV-serodiscordant couples in Uganda. Paper presented at: 7th International Conference on HIV Treatment and Prevention Adherence. Miami: 2012.
31. ClinicalTrials.gov. On demand antiretroviral pre-exposure prophylaxis for HIV infection in men who have sex with men (IPERGAY). http://clinicaltrials.gov/ct2/show/NCT01473472 (2013). Accessed 02 Oct 2014.
32. ClinicalTrials.gov. The ADAPT study: use of emtricitabine and tenofovir disoproxil fumarate for pre-exposure prophylaxis (PrEP). http://clinicaltrials.gov/ct2/show/NCT01327651?term=adapt&rank=7 (2014). Accessed 02 Oct 2014.